Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 23 Show results per page	View Search Criteria \| Help With Results

Last Modified: 6/1/1995


1.		Phase I/II Study of MOAB R24 in Combination with IL-2 and CTX in Patients with Metastatic Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				BRMP-8908C NCI-89-C-125C, NCI-T89-0065N, T89-0065

Last Modified: 8/1/1990


2.		Phase I/II Pilot Trial to Assess Immunosuppression of Human Anti-Mouse Antibody Response with Total Lymphoid Irradiation in Patients with Metastatic Melanoma Treated with Murine Monoclonal Antibody R24 (Summary Last Modified 08/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over								MSKCC-89159 NCI-V90-0034

Last Modified: 9/1/1991


3.		Phase I/II Study of CTX/IL-2/MOAB R24 in Patients with Metastatic Melanoma (Summary Last Modified 09/91)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over								LAC-USC-10M892 NCI-B90-0013, B90-0013


4.		Phase II Randomized Study of Immunotherapy with High-Dose vs Low-Dose Mouse Monoclonal Antibody R24 in Patients with Stage III/IV Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				MSKCC-85114A NCI-T86-0075C, T86-0075

Last Modified: 3/1/1988


5.		Phase II Randomized Study of High-Dose vs Low-Dose MoAb R24 in Patients with Metastatic Malignant Melanoma (Summary Last Modified 03/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				MSKCC-87124 NCI-T87-0294C, T87-0294

Last Modified: 8/1/1992


6.		Phase II Pilot Study of MOAB R24 Given in Conjuction with IL-2 in Patients with Metastatic Malignant Melanoma (Summary Last Modified 08/92)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				BRMP-9201 NCI-T92-0086N, NCI-92-C-0217

Last Modified: 9/1/1997


7.		Phase I Study of Monoclonal Antibodies Ch14.18 and R24 with IL-2 for Melanoma, Small Cell Lung Carcinoma, Soft Tissue Sarcoma, and Other GD2- and GD3-Positive Tumors (Summary Last Modified 09/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI				WCCC-CO-9391 NCI-B94-0002, B94-0002


8.		Phase I Study of R24 Mouse Monoclonal Antibody Against GD3 Ganglioside in Combination with Recombinant IL-2 in Patients with Metastatic Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				over 18								MSKCC-8612 NCI-B85-0011, B85-0011


9.		Phase I Immunotherapy with Anti-GD3 MoAb (MoAb R24) plus IFN-alpha in Patients with Unresectable Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over								CCF-1715 NCI-B85-0012, B85-0012

Last Modified: 8/1/1988


10.		Phase I Study of Anti-GD2 (3F8) and Anti-GD3 (R24) Mouse Monoclonal Antibodies in Patients with Metastatic Melanoma or Soft Tissue Sarcoma (Summary Last Modified 08/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over								MSKCC-86066 NCI-V88-0387

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute